MEK Inhibitors Reverse cAMP-Mediated Anxiety in Zebrafish  by Lundegaard, Pia R. et al.
Article
MEK Inhibitors Reverse cAMP-Mediated Anxiety in
ZebrafishGraphical AbstractHighlightsd PDE4 blockade/AC activation causes novel anxiety-like
behaviors in zebrafish
d Small-molecule screen identifies MEK inhibitors as
suppressors of cAMP anxiety
d Increased cAMP stimulates crosstalk to RAS-MAPK pathway
activity
d New therapeutic potential for MEK inhibitors to treat cAMP-
mediated anxietyLundegaard et al., 2015, Chemistry & Biology 22, 1335–1346
October 22, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.chembiol.2015.08.010Authors
Pia R. Lundegaard, Corina Anastasaki,
Nicola J. Grant, ...,
J. Douglas Armstrong,
David J. Porteous, E. Elizabeth Patton
Correspondence
e.patton@igmm.ed.ac.uk (E.E.P.),
david.porteous@ed.ac.uk (D.J.P.)
In Brief
Lundegaard et al. identify therapeutic
potential for anti-cancerMEK inhibitors to
treat anxiety-like cAMP-mediated
behaviors in zebrafish. Targeting cAMP-
MAPK crosstalk pathways broadens the
range of therapeutic targets for mental
health disorders. This work illustrates the
importance of whole-animal phenotypic
screening in anxiety drug discovery and
repurposing.
Chemistry & Biology
ArticleMEK Inhibitors Reverse cAMP-Mediated
Anxiety in Zebrafish
Pia R. Lundegaard,1,2,3,4,5,8 Corina Anastasaki,1,2,4,8 Nicola J. Grant,3,4,8 Rowland R. Sillito,6 Judith Zich,1,2,4
Zhiqiang Zeng,1,2,4 Karthika Paranthaman,1,2,4 Anders Peter Larsen,5 J. Douglas Armstrong,6,7 David J. Porteous,3,4,9,*
and E. Elizabeth Patton1,2,4,9,*
1MRC Human Genetics Unit, University of Edinburgh, Edinburgh EH4 2XU, UK
2Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XU, UK
3Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK
4Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK
5Department of Biomedical Sciences, Danish National Research Foundation Centre for Cardiac Arrhythmia, University of Copenhagen,
2200 Copenhagen, Denmark
6Actual Analytics Ltd, 2.05 Wilkie Building, 22-23 Teviot Row, Edinburgh EH8 9AG, UK
7School of Informatics, Institute for Adaptive and Neural Computation, Informatics Forum, University of Edinburgh, Edinburgh EH8 9AB, UK
8Co-first author
9Co-senior author
*Correspondence: e.patton@igmm.ed.ac.uk (E.E.P.), david.porteous@ed.ac.uk (D.J.P.)
http://dx.doi.org/10.1016/j.chembiol.2015.08.010
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARY
Alteredphosphodiesterase (PDE)-cyclicAMP (cAMP)
activity is frequently associated with anxiety disor-
ders, but current therapies act by reducing neuronal
excitability rather than targeting PDE-cAMP-medi-
ated signaling pathways. Here, we report the novel
repositioning of anti-cancer MEK inhibitors as anxio-
lytics in a zebrafish model of anxiety-like behaviors.
PDE inhibitors or activators of adenylate cyclase
cause behaviors consistent with anxiety in larvae
and adult zebrafish. Small-molecule screening iden-
tifies MEK inhibitors as potent suppressors of cAMP
anxiety behaviors in both larvae and adult zebrafish,
while causing no anxiolytic behavioral effects on
their own. Themechanism underlying cAMP-induced
anxiety is via crosstalk to activation of theRAS-MAPK
signaling pathway. We propose that targeting cross-
talk signaling pathways can be an effective strategy
for mental health disorders, and advance the reposi-
tioning ofMEK inhibitors as behavior stabilizers in the
context of increased cAMP.
INTRODUCTION
Mental health conditions afflict one in four adults in their life-
time, with generalized anxiety being the most commonly diag-
nosed mental health disorder in Western countries (Griebel and
Holmes, 2013). There is an urgent need for therapeutic targets
and therapies for anxiety, and for the development of new animal
models of behavior to be incorporated into anxiolytic drug
research (Baldwin, 2011).
The secondmessengers cyclic AMP (cAMP) and cyclic guano-
sinemonophosphate (cGMP) are critical in the signaling that con-Chemistry & Btrols learning, memory, and mood (Maurice et al., 2014; Xu et al.,
2011). Intracellular levels of cAMPand cGMPare tightly regulated
by tissue-specificphosphodiesterases (PDEs) that catalyzecyclic
nucleotide hydrolysis. Genetic and pharmacological evidence in-
dicates that the PDE4 genes have an important role in controlling
cAMP levels in the CNS and behavior (Maurice et al., 2014; Xu
et al., 2011). In mammals, PDE4 enzymes comprise four subfam-
ilies (PDE4A–D). Polymorphisms in humanPDE4B are associated
with schizophrenia; we have previously reported complete
disruption of the PDE4B gene in two independent subjects with
psychosis, and that PDE4B and PDE4D interact dynamically
with the schizophrenia candidate gene DISC1 to regulate cAMP
(Clapcote et al., 2007; Millar et al., 2005, 2007). New PDE4 inhib-
itors are the focus of intensive drug discovery, not least because
recent genome-wide studies indicate that PDE4 may be involved
in the pathogenesis of stroke (Nilsson-Ardnor et al., 2005; Staton
et al., 2006), bone density (Reneland et al., 2005), and asthma
(Hansen et al., 2000; Himes et al., 2009). Underscoring the
importance of PDE4 inhibitors in disease, the PDE4 inhibitor roli-
pram has been reported to have potential as a neuroprotectant,
as well as enhance cognition and rescue memory deficits in
models of Huntington’s disease, Alzheimer’s disease, diabetes,
or following brain injury (DeMarch et al., 2008; Burgin et al.,
2010; Cheng et al., 2010; Miao et al., 2015; Titus et al., 2013).
Rolipram is highly specific to PDE4 and is effective in mam-
mals; however, it causes severe emesis in human patients,
making it unsuitable as a clinical drug (O’Donnell and Zhang,
2004). In animal studies, pharmacological inhibition of PDE4
can have anti-depressive, sedative, anxiolytic, anti-psychotic,
and cognitive enhancing effects, and can increase neurogene-
sis, but conversely the drug can have anxiogenic effects in
some contexts (Burgin et al., 2010; Heaslip and Evans, 1995;
Li et al., 2009; Rutten et al., 2008; Silvestre et al., 1999; Siuciak
et al., 2007; Zhang et al., 2002). This range of rolipram-induced
behaviors likely reflects the importance of specific PDE4 sub-
types in regulating distinct behaviors: genetic studies in mice
have revealed that anxiety is largely regulated by PDE4A andiology 22, 1335–1346, October 22, 2015 ª2015 The Authors 1335
PDE4B, psychosis by PDE4B, and depression and cognition by
PDE4D (Hansen et al., 2014; Li et al., 2011; Siuciak et al., 2007,
2008; Zhang et al., 2002, 2008). DISC1 and PDE4B may also be
important in the development of depression caused by chronic
stress (Zhang et al., 2015). Notably, the anti-psychotic effects
of rolipram and the dependence of these effects on PDE4B are
consistent with the association of PDE4B gene disruptions
with schizophrenia (Millar et al., 2005; Siuciak et al., 2007; Zhang
et al., 2008).
While strong genetic evidence in mice indicates the impor-
tance of PDE4A/B in anxiety (Hansen et al., 2014; Zhang et al.,
2008), the mechanism through which PDE4-cAMP leads to
anxiety remains unknownwhile being critical for the development
of new therapeutic approaches and targets. In zebrafish, PDE4
inhibitors promote anxiety-like behaviors, including decreased
habituation to the startle response, increased activity, and thig-
motaxis (wall-hugging) in larvae and adult fish (Best et al., 2008;
Maximino et al., 2011; Richendrfer et al., 2012; Schnorr et al.,
2012; Stewart et al., 2011). Here, we develop a zebrafish model
for PDE4-cAMP-mediated anxiety-like behaviors, and use this
model to discover chemical suppressors of anxiety in an unbi-
ased, whole-animal phenotypic small-molecule screen. Through
screening 80 kinase inhibitors, wediscoverMEK inhibitors (MEKi)
to be highly effective anxiolytics for PDE4-cAMP-mediated
anxiety-like behavior in larvae and adult zebrafish. Inhibitors of
the mitogen-activated protein kinase (MAPK) signaling pathway
have been the focus of intense pharmaceutical interest as tar-
geted cancer therapies. We report the effective use of MEKi to
treat anxiety-like behaviors in zebrafish, and demonstrate a
new potential for the repurposing of MEKi as anxiolytics.
RESULTS
PDE Blockade/Adenylate Cyclase Activation Induces a
Novel Anxiety Response in Zebrafish
We previously identified disruption of PDE4B in two cousins,
one diagnosed with schizophrenia and the other with psychosis
(Millar et al., 2005). To gain insight into the role of PDE4 in
behavior, we modeled the effects of PDE4 inhibition in zebrafish,
and developed a small-molecule phenotypic screening platform
for novel treatments of PDE4-associated behaviors. Zebrafish
are a relevant model system for the study of behavioral disorders
because they share homologous molecular and genetic mecha-
nisms with humans, are amenable to genetic and chemical
screening, and display defined behaviors, including clear indica-
tors of anxiety and fear (Egan et al., 2009; Blaser et al., 2010; Nor-
ton and Bally-Cuif, 2010; Rihel and Schier, 2012; Stewart et al.,
2011; Wolman and Granato, 2012). Zebrafish embryos were
placed in an open arena (10-cm Petri dish with 30 ml of E3 fish
water) and their position was recorded when treated with the
PDE inhibitors rolipram or 3-isobutyl-1-methylxanthine (IBMX),
or the adenylate cyclase (AC) activator, forskolin (Figures 1A–
1D). Rolipram-, IBMX-, or forskolin-treated embryos showed a
dramatic and significant thigmotaxic response, whereby the
fish swam rapidly to the edge of the dish (Figures 1A–1D; Movies
S1 and S2; Figure S1). Unlike other described zebrafish thigmo-
taxis assays (Richendrfer et al., 2012; Schnorr et al., 2012), there
was no experimental trigger in the open arena. Close examina-
tion of the fish at the edge of the dish revealed a shadow at the1336 Chemistry & Biology 22, 1335–1346, October 22, 2015 ª2015 Trim of the dish (Figure 1A). We found that the thigmotaxic
behavior was dependent on the ability of the fish to detect differ-
ences in light conditions (Figure 1C). Caffeine, a well-established
anxiogenic drug in mammals and zebrafish and a non-selective
PDE inhibitor, was used as a positive control (Figure 1E),
providing corroborating evidence that the open-field thigmotaxic
response is an anxiety-like behavior in zebrafish larvae.
PDE Blockade/AC Activation Induces Hyperactivity
We hypothesized that PDE blockade/AC activation could
stimulate additional anxiety-like behaviors in zebrafish, such
as hyperactivity, as measured by increased swimming activity.
Zebrafish larvae were arrayed individually into wells of a 96-
well plate, treated with compound for 1 hr, and swimming activity
was tracked and recorded for a further hour (Figure 1F). Zebra-
fish treated with PDE blockade/AC activation agents showed
significantly enhanced activity in both the light and the dark
(Figures 1F–1H). Notably, rolipram-induced hyperactivity was
sustained over 5 hr (Figure 1H). Comparison of the data distribu-
tion histograms in Figure 1H for DMSO-treated zebrafish and
rolipram-treated fish revealed a complex response to rolipram.
Not only did rolipram significantly increase themean activity level
over 1 hr in the dark compared with DMSO-treated fish, it also
divided fish into two distinct populations (dashed line in Fig-
ure 1H; see also Experimental Procedures).
Small-Molecule Screening for Chemical Suppressors of
Anxiety-like Behaviors
Having established a robust thigmotaxic response to PDE4
blockade/cAMP activation, we wanted to identify small mole-
cules that could restore normal behavior. Eighty kinase in-
hibitors taken from the Screen-Well Kinase Inhibitor Library
(EnzoLifeSciences) were screened to identify compounds that
could reverse the rolipram-induced thigmotaxic response.
First, zebrafish larvae were treated with 15 mM rolipram to
evoke the thigmotaxic response. Next, 15 mM of each of the
kinase inhibitors was added to the water, the plate was swirled
to ensure even distribution of the inhibitor in the water, and the
position of the fish was recorded 1 hr later. Control-treated
embryos rapidly reestablished themselves at the edge of the
dish (Figure 2B). The most potent thigmotaxis inhibitors were
the MEKi PD98059, and the growth factor receptor inhibitors
Tyrphostin 25 and Tyrphostin AG-370.
Given the potent effect of the MEKi PD98059 in our screen, we
tested the effect of PD0325901, a chemically divergent, clinically
active and highly specific MEKi (Samatar and Poulikakos, 2014)
on PDE4 blockade/cAMP activation (Figures 2B and 2C). Addi-
tion of 1 mM PD0325901 significantly rescued the thigmotaxic
effects of PDE4 blockade/cAMP activation within 30–40 min.
These results were corroborated by the results from the activity
assay (Figures 2D–2F). As in Figure 1H, rolipram treatment
divided fish into two distinct populations made apparent by
two peaks in the distribution histogram (Figure 2E). MEKi treat-
ment was anxiolytic for rolipram-induced hyperactivity (Figures
2D–2F), supporting a role for MEKi in treating anxiety.
cAMP-RAS-MAPK Pathway Crosstalk in Anxiety
Because of the sensitivity of PDE4 blockade/cAMP activa-
tion anxiety-like phenotypes to MEKi, we hypothesized that thehe Authors
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Figure 1. PDE Blockade/AC Activation Stimulates Thigmotaxis and Hyperactivity in Zebrafish Larvae
(A and B) Images and schematic representation of thigmotaxis in an open arena following PDE4 blockade/AC activation.
(C and D) Quantification (C) and representative image (D) of zebrafish larvae (3 dpf) in 10-cm Petri dish. Larvae exhibiting thigmotaxis are highlighted with orange
dots, and non-thigmotaxic larvae with blue dots. Experimental repetitions: n = 7 with 24–35 larvae per treatment condition. Drug treatment concentrations:
rolipram 15 mM, forskolin 7.5 mM, IBMX 30 mM.
(E) Thigmotaxic response following caffeine treatment. Experimental repetitions: n = 3 (in light and dark) with 35–43 larvae per treatment.
(F) Images of individual zebrafish larval traces (1 hr of tracking) in 96-well plate wells.
(G) Swimming activity of zebrafish larvae (5 dpf) treated with PDE4 blockers/cAMP activators in light or dark conditions (1 hr treatment, 30 min tracking in the light
or dark). Experimental repetitions: n = 4 with 24 larvae per treatment condition. Drug treatment concentrations: rolipram 15 mM, forskolin 7.5 mM, IBMX 30 mM.
(H) Histograms showing distribution of total distance moved (normalized values) in response to DMSO (larvae, n = 48) and rolipram (larvae, n = 48), with swimming
activity followed over 5 hr. The last 10 min of the first and fifth hour are plotted. Dashed line indicates the approximate separation between the two populations.
L, light conditions; D, dark conditions. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA; Tukey’s multiple comparison test). Error bars denote SEM. See also
Movies S1 and S2; Figure S1.
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Figure 2. MEKi Reverse Behaviors Caused by PDE4 Blockade/AC Activation
(A) Schematic overview of small-molecule screen for suppressors of thigmotaxic behavior.
(B and C) Images (B) and quantification (C) of behavior of zebrafish larvae in an open arena. Orange dots: thigmotaxic behavior; blue dots: non-thigmotaxic
behavior. Experimental repetitions: n = 6/7 with 25–35 larvae per treatment condition.
(legend continued on next page)
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underlying molecular mechanism was via activation of the
MAPK signaling pathway. First, we confirmed that rolipram and
forskolin treatment led to increased cAMP levels in zebrafish
larvae, and that these remained significantly increased in em-
bryos co-treated with MEKi (Figure 3A). Next, MAPK pathway
activity was investigated by collecting zebrafish embryos treated
with rolipram for an hour, then treated with or without MEKi for
another hour, and western blotting for phospho-ERK and ERK
proteins. Importantly, as shown in Figure 3B, a significant in-
crease in phospho-ERK signal was clearly detected upon roli-
pram treatment in 5-dpf (days post fertilization) embryos (Figures
3B and 3C), revealing that rolipram treatment leads to activation
of theMAPK signaling pathway in zebrafish larvae. Co-treatment
with MEKi abolished MAPK pathway activation (Figures 3B
and 3C), correlating with the restored behaviors observed in
the PDE4 blockade-MEKi combined treatment regimes. To
confirm the specificity and establish the molecular mechanism
through which rolipram regulates ERK signaling, we assayed
RAS activity after rolipram treatment of 5-dpf embryos. Similar
to ERK1/2 phosphorylation, we found a significant increase in
active RAS (RAS-GTP) following dose-dependent rolipram treat-
ment (Figures 3D and 3E). Collectively, our results demonstrate
that increasing doses of rolipram promote cAMP-RAS-MAPK
pathway activation.
MEKi Submaximal On-Target Activity to Treat Anxiety
MEKi are potent targeted therapies designed to effectively shut
off the MAPK signaling in cancers with activating mutations in
RAS and BRAF (Samatar and Poulikakos, 2014). We wanted to
test whether full MAPK pathway inhibition was essential to treat
anxiety-like behaviors, or whether anxiolytic effects could be
induced by partial on-target pathway inhibition. Zebrafish em-
bryos were treated with rolipram and 0.1 mM MEKi, a 15-fold
dose reduction compared with experiments presented in Fig-
ures 2 and 3. Western blotting of zebrafish lysates indicated
that 0.1 mMMEKi partially inhibits phospho-ERK1/2 (67% phos-
pho-ERK compared with levels in the DMSO treatment; Fig-
ure 4A). Anxiolytic effects of 0.1 mM MEKi on rolipram-treated
embryos were evident in both the thigmotaxis assay (3 dpf; Fig-
ure 4B) and the larval activity assay (5 dpf; Figure 4C). Thus, par-
tial inhibition of the MAPK pathway is effective in ameliorating
anxiety-like behavior, albeit less effectively than at higher doses,
and reveals potential for MEKi treatments to be customized for
variable pathway inhibition depending on the disease context.
MEKi Treatment for Anxiety in Adult Zebrafish
To increase the translational impact of our finding, we tested
whether MEKi treatment could alleviate anxiety-like behaviors
due to PDE4 blockade in adult zebrafish, rather than during the(D) Images of individual zebrafish larval traces in 96-well plate. Zebrafish were tre
tracked for 1 hr.
(E) Histograms showing distribution of total distance moved (normalized values)
larvae), rolipram with MEKi PD0325901 (n = 227 larvae), and MEKi PD0325901 (
(F) Total distance moved (normalized values from Figure 2E). Means and bootstrap
the DMSO-treated fish to facilitate comparison with this group. Due to the non-
compared by assessing the bootstrapped 95% CI of the differences between gr
Drug treatment concentrations: rolipram 15 mM, forskolin 7.5 mM, IBMX 30 mM,ME
comparison test). Error bars denote SEM.
Chemistry & Bstages of active neuronal development. We tracked groups of
five adult sibling zebrafish from the side view for their placement
preference in a tank with 1.0 l of water (group behavior assay;
n = 6 experimental replicates) (Figures 5A and 5B). Rolipram-
treated fish showed a distinct preference for the bottom of their
container, consistent with increased anxiety (Figures 5A and 5B).
Critically, MEKi treatment restored the normal tank distribution of
rolipram-treated adult zebrafish compared with PDE4 blockade
alone (Figures 5A and 5B). Rolipram-treated zebrafish had
increased levels of cortisol, an indicator of increased levels of
stress, which was significantly reduced upon addition of MEKi
(Figure 5C).
Notably, unlike currently available anxiolytics, yet consistent
with larval studies in Figures 2, 3, and 4, we found no evidence
for MEKi to exert anxiolytic effects alone in adult zebrafish.
This was further supported in the novel tank assay (Egan et al.,
2009), whereby single adult zebrafish were tracked for 5 min
when placed in a novel tank (3 l) and comparedwith the anxiolytic
buspirone (a serotonin receptor 5-HT1A partial agonist) and
rolipram as an anxiogenic. Fish treated with the anti-anxiety
drug buspirone displayed anxiolytic effects, such as reduced
time to explore the upper regions of the tank, while MEKi treat-
ment alone had no effect on zebrafish behavior (Figure S2).
Thus, we find that MEKi are potent anxiolytics in adult zebrafish
with cAMP-mediated anxiety, but show no anxiolytic effects
when used as single agents.
DISCUSSION
Both genetic and environmental factors contribute to anxiety
and depression disorders. Human genetics and pharmacology
indicate that PDE4 has an important function in behavior. How-
ever, treatment for anxiety is centered on sustaining signaling
in postsynaptic neurons, and these treatments vary in their effec-
tiveness and are often associated with unwanted side effects
(Baldwin, 2011; Griebel and Holmes, 2013; Maurice et al.,
2014). Here, we have developed an alternative strategy to iden-
tify context-specific anxiolytics by first developing a zebrafish
model for PDE4 blockade/cAMP anxiety-like behavior and then
undertaking an in vivo phenotypic screen for suppressors of
zebrafish anxiety behaviors. We discover that treatment with
MEKi, originally developed as anti-cancer agents, are effective
anxiolytics in the context of PDE4 blockade/cAMP activity (Fig-
ure 6). Rolipram-induced anxiety-like behaviors lead to an in-
crease in GTP-bound (active) RAS and phospho-ERK levels in
zebrafish embryos (Figures 3C and 3D). MEKi treatment leads
to a reduction in phospho-ERK levels and anxiety-like behaviors
(Figures 2, 3, 4, and 5). Importantly, unlike clinically active anxi-
olytics such as buspirone, our studies here indicate that theated for 1 hr with rolipram followed by 1 hr treatment with or without MEKi, and
in response to treatment conditions: DMSO (n = 143 larvae), rolipram (n = 185
n = 149 larvae).
ped 95%CIs are shown. Dotted lines indicate the upper and lower CI limits for
normal distribution and unequal variance of data across groups, means were
oups.
Ki 1.5 mM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA; Tukey’s multiple
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Figure 3. Crosstalk between cAMP and ERK Signaling Pathways
(A) Total cAMP concentration in zebrafish larvae (5 dpf) following treatment with rolipram (15 mM) or forskolin (7.5 mM) (1hr), followed by treatment with or without
MEKi PD0325901 (1.5 mM) (1 hr). Experimental repetitions: n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA, Tukey’s multiple comparison test).
(B and C) Western blotting (B) and quantification (C) of zebrafish extracts following treatment with rolipram (1 hr) and/or 1.5 mM MEKi PD0325901 (1 hr), and
probed with antibodies to ERK1/2 and phospho-ERK1/2. Experimental repetitions: n = 4. **p < 0.001 (one-way ANOVA; Tukey’s multiple comparison test).
(D and E) Western blotting (D) and quantification (E) of levels of active RAS (RAS-GTP) following immunoprecipitation with Raf-1-bound agarose beads. Probed
with antibodies to RAS-GTP and RAS. Experimental repetitions: n = 3 (n = 2 for 30 mM).
***p < 0.05 (one-way ANOVA; Tukey’s multiple comparison test).
Error bars denote SEM.MEKi have no anxiolytic effects alone (Figures 2, 3, 4, 5, and S2),
suggesting that they may be an improvement over current ther-
apeutic approaches for anxiety.
In mice, regulation of anxiety is largely mediated by PDE4A
and PDE4B (Hansen et al., 2014; Zhang et al., 2008). Here,
we hypothesize that the anxiety-like behaviors of rolipram in
zebrafish are mediated through inhibition of Pde4A/B because:1340 Chemistry & Biology 22, 1335–1346, October 22, 2015 ª2015 T(1) mouse and zebrafish PDE4A/B genes are highly conserved
(Pde4a: 73% identity; Pde4ba: 75% identity; Pde4bb: 72%
identity); (2) the anxiety-like behaviors of rolipram in zebrafish
are consistent with the anxiety phenotypes of pde4a and
pde4b mutant mice (Hansen et al., 2014; Zhang et al., 2008);
and (3) rolipram in zebrafish leads to an increase in cortisol level,
which is also consistent with increased plasma corticosteronehe Authors
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Figure 4. MEKi Treatments at Submaximal On-Target Concentrations Relieve Anxiety
(A) Western blotting of zebrafish extracts following treatment with rolipram (1 hr) and/or MEKi PD0325901 at 1.5 mMor 0.1 mM (1 hr), and probedwith antibodies to
ERK1/2 and phospho-ERK1/2. Experimental repetitions: n = 3.
(B) Thigmotaxis assay (3 dpf) with 15 mM rolipram and/or 1.5 mM or 0.1 mM MEKi treatment. Experimental repetitions: n = 3.
(C) Swimming activity of zebrafish larvae (5 dpf) following treatment with rolipram (1 hr) with or without MEKi (1 hr). Images of individual zebrafish larval traces from
representative wells in a 96-well plate (1 hr). Experimental repetitions: n = 2 with 24 larvae per treatment group.
**p < 0.01; ***p < 0.001 (one-way ANOVA; Tukey’s multiple comparison test). Error bars denote SEM.levels in pde4a and pde4b mouse genetic mutants (Hansen
et al., 2014; Zhang et al., 2008). Interestingly, unlike PDE4B,
PDE4A lacks an ERK phosphorylation site (Baillie et al., 2000;
Zhang, 2009), suggesting that PDE4B may have the potential
to be directly regulated by MAPK signaling. Finally, in contrast
to the effects of rolipram treatment, our genetic studies indicate
that adult pde4d/ zebrafish mutants have anxiolytic behav-
iors, including an increase in shoal size and increased tank
exploration, compared with pde4d+/+ wild-type siblings (Figures
S3B and S3C). In addition, pde4d/ mutants respond to the
anxiogenic effects of rolipram (Figure S3E), indicating that the
targets of rolipram in anxiety are via other PDE4 subfamilies
and not PDE4D.
Rolipram also has sedative effects in mice that may be linked
to inhibition of PDE4D (e.g. Hu et al., 2011). We did not observe
sedative effects in zebrafish, possibly because the primary
rolipram PDE4 targets in zebrafish are more likely PDE4A or
PDE4B; however, we do find that pde4d mutant fish swim less
overall distance compared with sibling controls (Figure S3D).
Interestingly, some larvae appear to be hyper-responsive to roli-
pram in the activity assay (Figures 1H and 2E). At this stage, we
do not know whether this reflects subpopulations of zebrafish
with differences in PDE4 expression and regulation of anxiety,
or whether there are individual differences in drug uptake and
metabolism. Further spatial and temporal expression studies
on PDE4 subfamilies, coupled with genetic mutants, will be
important in dissecting PDE4 functions in anxiety. For example,
PDE4B expression in mice is highest in regions of the brain asso-
ciated with anxiety (Cherry and Davis, 1999; Engels et al., 1995;
Perez-Torres et al., 2000; Zhang et al., 2008).Chemistry & BAn important aspect of drug development is the repositioning
(repurposing) of available drugs used to treat one disease for the
treatment of a different disease. The MAPK pathway has been
shown to interact with PDE4D (Hoffmann et al., 1999; Sheppard
et al., 2014; Zhang et al., 2004), but to date has not been
associated with other PDE4 subfamilies and anxiety, providing
new opportunities for treating anxiety. Highly selective MEKi
are currently in clinical trial for ovarian and thyroid cancer, and
for use alone or in combination with BRAFV600E inhibitors in mel-
anoma (Samatar and Poulikakos, 2014). We, and others, have
previously proposed that MAPK pathway inhibitors may hold
promise for the management of syndromes with germ-line acti-
vating mutations in the RAS-MAPK pathway (the RASopathies)
(Anastasaki et al., 2009, 2012; Pagani et al., 2009; Rauen,
2013; Runtuwene et al., 2011; Tidyman and Rauen, 2009; Viosca
et al., 2009; Wolman et al., 2014; Wu et al., 2011). Notably, one
of the clinical features associated with the RASopathies is
increased anxiety (Axelrad et al., 2011), consistent with our
findings that increased MAPK signaling is anxiogenic. Of note,
rolipram can reverse memory deficits induced by infusion of
the MEKi U0126, suggesting PDE4-MEK crosstalk may also be
active in memory formation (Zhang et al., 2004). Based on animal
models, the potential for unwanted effects of MEKi on memory
may require clinical investigation, although such symptoms
have not been reported in cancer clinical trials (trametinib pre-
scribing information, US Food and Drug Administration).
It will be important to compare the effective concentration
of MEKi in the context of cancer compared with behavior disor-
ders. In our zebrafish RASopathy models, continuous treatment
with low doses of MEKi restored normal development withoutiology 22, 1335–1346, October 22, 2015 ª2015 The Authors 1341
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Figure 5. MEKi Ameliorate Anxiety Behaviors in Adult Zebrafish
(A) Group behavior assay of adult zebrafish, following 20-min incubation in 1 l of system water with indicated treatments. Behavior was recorded from the side
and the distribution in the tank analyzed. Experimental repetitions: n = 6 with 25 adult fish per treatment condition. ***p < 0.001 (two-way ANOVA; Bonferroni
post-test).
(B) Bird-nest representations of the tracks of groups of five adult zebrafish taken from the side of a 1-l tank, and activity heatmap corresponding to relative amount
of time spent by the fish in areas of the tank during a 5-min period. Maps are 2D Kernel Density Estimates derived from animal coordinates, rendered with a
custom color map to enhance visibility: clear (none/minimal), blue (low), through to red (high). Experimental repetitions: n = 6.
(C) Cortisol levels of treated adult zebrafish (n = 5 individual fish). *p < 0.01 (one-way ANOVA; Tukey’s multiple comparison test).
Error bars denote SEM. See also Figure S2.additional unwanted developmental effects of MAPK pathway
inhibition (Anastasaki et al., 2012). For cancer treatment, higher
concentrations may be needed to shut off the MAPK pathway,
while lower doses may be effective in restoring normal MAPK
signaling in the treatment of anxiety. Thismay have important im-
plications for minimizing the unwanted effects of MAPK pathway
inhibition. Here, we find that partial inhibition of MAPK signaling
is sufficient to reduce anxiety-like behaviors in zebrafish, indi-
cating that submaximal on-target activity may be efficacious in
treating anxiety-like behaviors (Figure 4). However, we observed
that low-dose MEKi treatment was not fully efficacious in the
activity assay (Figure 5C), suggesting that dysregulation of the
MAPK pathway by ectopic activation, in addition to the total
levels of MAPK signaling, contribute to anxiety phenotypes.
In conclusion, we present the conceptual advance that target-
ing the MAPK crosstalk signaling pathway is a novel therapeutic
approach to treat PDE4-cAMP-mediated anxiety. We propose
that PDE4-MEK crosstalk regulates anxiety-like behaviors, and1342 Chemistry & Biology 22, 1335–1346, October 22, 2015 ª2015 Tthat highly specific MEKi, originally designed as anti-cancer
therapies, may have repositioning potential as anxiolytics (even
at submaximal on-target doses) in the context of increased
cAMP. Our work underscores the power in drug discovery of un-
biased phenotypic small-molecule screening in zebrafish and
drug repurposing for mental health disorders.
SIGNIFICANCE
Anxiety disorders are among the most common mental
health disorders, afflicting 10%–20% of the Western adult
population during their lifetime. Currently available drug
treatments act by dampening neuronal excitability, are
limited in their efficacy, and can have unwanted side effects.
Here, we propose that the clinically effectiveMEKi, originally
designed to treat cancer, may be repurposed as anti-anxiety
drugs for patients with high-cAMP-induced anxiety. First,
we developed a model of anxiety-like behaviors by treatinghe Authors
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Figure 6. A Novel Therapeutic Strategy: MEK Inhibitors to Treat cAMP-Mediated Anxiety
Schematic for the repositioning of MEKi as novel therapeutics for PDE4 blockade/AC activation anxiety. In control fish, PDE4 is a negative regulator of cAMP
activity. PDE4 blockade/AC activation leads to increased cAMP activity and activation of the MAPK signaling pathway, and is anxiogenic. Treatment with MEKi
reduces MAPK activity and is anxiolytic.zebrafish with inhibitors of PDE4 or activators of cAMP. This
model is relevant because cAMP levels play a critical role in
behavior, and we have previously shown that disruptions in
PDE4B are associated with mental health disorders. Next,
we performed a small-molecule screen for compounds
that can restore normal behavior in our zebrafish anxiety-
like model. Phenotypic drug screening is important because
it enables us to identity drug leads in an unbiased fashion
and reveals new targets in a live animal. We discover that
MEKi are highly effective anxiolytics in zebrafish, and that
the mechanism of PDE4 blockade/cAMP activation induced
anxiety is via stimulation of the RAS-MAPK signaling path-
way. cAMP-MAPK signaling crosstalk in anxiety has not
been previously reported, and is significant because it re-
veals that targeting the crosstalk MAPK signaling pathway
offers a potent alternative therapeutic strategy for anxiety.
Notably, our zebrafish studies indicate that unlike in cancer
treatment, MEKi may be effective at low treatment doses
that promote only partial, on-target MAPK inhibition,
thereby potentially minimizing drug-induced side effects.
In conclusion, the conceptual advance we present here
is that targeting the crosstalk MEK signaling pathway is a
new anxiolytic target, and that anti-cancer MEKi have the
potential to be repurposed as anxiolytics for cAMP-medi-
ated anxiety.EXPERIMENTAL PROCEDURES
Zebrafish work was conducted according to the standards and ethical guide-
lines established by the University of Edinburgh and the Home Office of the
United Kingdom (Animal Scientific Procedures Act, 1986), and the University
of Copenhagen and the Danish Animal Experiments Inspectorate.
Drug Treatments, Thigmotaxis Assay, and Small-Molecule Screen
For zebrafish chemical treatments, forskolin, rolipram, and IBMX (all from Toc-
ris Bioscience), caffeine (Sigma-Aldrich), and PD0325901 (University of Dun-
dee, UK) were prepared in DMSO. We noted some batch-to-batch variability
for rolipram. For the kinase library screen (EnzoLifeSciences Screen-WellChemistry & BKinase Inhibitor Library), three dpf wild-type embryos were incubated in
15 mM rolipram in 10-cm Petri plates to establish thigmotaxis, then the kinase
inhibitor was added (final concentration 15 mM), the plate swirled, and the dish
observed 1 hr later.
Live Larval 96-Well Tracking
Individual 5-dpf embryos were distributed into a well of a 96-well plate, in
100 ml of E3 embryo medium, and allowed to habituate for 1 hr prior to drug
treatment. Following 1 hr of drug treatment, the behavior of the larvae was
tracked for another hour in the DanioVison Observation Chamber and the
behavior was analyzed using EthoVision XT 8.5 software (Noldus Information
Technology). For the swimming activity data shown in Figure 1H, data were
pooled across several plates to better examine data distributions. In these ex-
periments data were normalized to the grand average of each individual plate
to minimize plate-to-plate variation.
Western Blots
Following drug treatment, larvae were snap-frozen in liquid nitrogen and pro-
tein was extracted using lysis buffer: 20 mM Tris-HCl, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, and 30 mM NaF, with PhosStop and
CompleteMini inhibitors (Roche). Larvae were disrupted using a hand-held
pestle and allowed to incubate on ice for 15 min, prior to spinning at
14,000 rpm for 15 min at 4C. Protein samples were run on gradient gels
(4%–20% TGX-gels; Bio-Rad), and transferred to an Immobilon-FL PVDF
membrane (Millipore). Blocking and antibody incubation was done in Odyssey
Blocking Buffer diluted 1:1 in PBS. Antibodies were anti-phospho-p42/44
(1:2,000; Cell Signaling Technology) and anti-p42/44 (1:1,000; Cell Signaling
Technology). Secondary antibodies were IRDye labeled donkey anti-mouse
antibody (1:15,000) and goat anti-rabbit antibody (1:15,000).
Adult Group Behavior Analysis
Groups of five wild-type fish were incubated for 20 min in 1.0 l of system water
plus DMSO or compound, and recorded and tracked (5min) from the side. Due
to batch variability, rolipram was used at concentrations of 20–40 mM. Exper-
iments in Figure 5 were repeated six times (five times as blinded study). Swim-
ming fish were recorded with a Panasonic Lumix DMC-TZ8 camera and each
recording tracked using ActualTrack (Actual Analytics).
Cortisol Determination
Fish from Figures 5A and 5B were immersed in ice-water, the brain tissue
removed, and cortisol extracted using diethylether as described previously
(Barcellos et al., 2007), with the samples left overnight for ether evaporation
as described by Cachat et al. (2010). Following evaporation, cortisol wasiology 22, 1335–1346, October 22, 2015 ª2015 The Authors 1343
reconstituted in PBS, and cortisol levels were determined using an ELISA kit
(Salimetrics Europe).
Cyclic AMP Extraction
Zebrafish larvae (5 dpf; n = 15 per treatment per experiment) were snap-frozen
in liquid nitrogen. cAMP was extracted by homogenizing samples using a
hand-held homogenizer with pestle in 200 ml of 0.1 M HCl. Samples were son-
icated for 15 s and spun at 13,000 rpm (15 min at 4C). Supernatant was trans-
ferred to a fresh Eppendorf tube and cAMP concentration was determined
(Direct cAMP ELISA kit; Enzo Life Sciences).
RAS Activity Assays
RAS activity (RAS-GTP) was measured by Raf-1 RBD immunoprecipitation
using the RAS Activation Assay Kit (Millipore), following the manufacturer’s
instructions. Specifically, 30 embryos from each treatment group were
snap-frozen and lysed by sonication in 200 ml of RAS lysis buffer supplemented
with 1 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mMPMSF. 150 mg of total pro-
tein lysate was immunoprecipitated with 5 ml of RAS assay reagent (Raf-1 RBD
agarose beads) in a 250-ml reaction. 150 mg of control-treated embryo lysate
supplemented with 100 mM GTPgS was used as a technical positive control.
Following overnight incubation at 4C, the beads were collected by centrifuga-
tion, washed three times in RAS lysis buffer, boiled in 20 ml of 23 Laemmli
buffer supplemented with b-mercaptoethanol, and loaded on a 10% poly-
acrylamide gel. 25 mg of total protein lysate was used as a loading control.
RAS-GTP and total RAS levels were detected by western blotting using the
mouse monoclonal pan-RAS antibody (anti-RAS clone RAS10) provided and
horseradish peroxidase-conjugated secondary antibody, and the signal was
detected using ECL chemiluminescence (Thermo Scientific).
Statistical Analysis
GraphPad Prism 5 and R (v3.0.2; www.r-project.org) software was used
for statistical analysis. Tests included one-way and two-way ANOVA, fol-
lowed by Tukey’s post-test or Bonferroni’s post-test. Data were plotted as
the mean, with error bars representing SEM. For data found to be non-
normal and with unequal variance across groups, 95% confidence intervals
(CIs) of the group means and the difference between group means were esti-
mated by bootstrapping (CIs were bias-corrected and accelerated and
based on 10,000 resamplings). Means were considered significantly different
when the bootstrapped 95% CI (of the difference between means) did not
include zero.
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